Milnacipran (Savella – Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a gamma-aminobutyric acid (GABA) analog similar to gabapentin also approved for treatment of diabetic neuropathy, post-herpetic neuralgia and epilepsy,1 and duloxetine, an SNRI also approved for treatment of depression, diabetic neuropathy and generalized anxiety disorder.2

FIBROMYALGIA — Fibromyalgia is characterized by chronic musculoskeletal pain, tenderness, fatigue and sleep disturbance. Genetic, environmental and psychosocial factors appear to influence its expression.3-5

In addition to the FDA-approved drugs, medications used to treat fibromyalgia have included analgesics, muscle relaxants, anticonvulsants, and antidepressants ... more      

Would you like to read the rest of this article?  Gain access below.